España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
PURE Bioscience
PURE
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.0769
0.00353
4.80%
At close: -
$0.0700
-0.00690
-8.97%
After Hours: Jun 27, 8:41 AM EDT
Get Report
Comment
PURE Bioscience (PURE) Forecast
News
Earnings
PURE Bioscience (PURE) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for PURE Bioscience (OTC:PURE) Stock
PURE Bioscience Stock (OTC: PURE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 01, 2024
PURE Bioscience Announced A Multi-Year Distri...
Benzinga Newsdesk
Wednesday, June 14, 2023
PURE Bioscience Q3 EPS $(0.01), Same YoY, Sal...
Benzinga Newsdesk
Tuesday, June 15, 2021
Pure Bioscience Q3 EPS $(0.01) Down From $0.01 YoY, Sales $556.00K Down From $2.22M YoY
Bill Haddad
Thursday, March 12, 2020
PURE Bioscience Q2 EPS $(0.01) Up From $(0.02...
Benzinga Newsdesk
Friday, February 28, 2020
Stocks That Hit 52-Week Highs On Friday
Lisa Levin
Wednesday, February 05, 2020
Stocks That Hit 52-Week Highs On Wednesday
Lisa Levin
Monday, October 21, 2019
Stocks That Hit 52-Week Lows On Monday
Lisa Levin
Wednesday, August 21, 2019
Stocks That Hit 52-Week Lows On Wednesday
Lisa Levin
Wednesday, July 31, 2019
New 52-Week Low Achievers for Wednesday Morning
Lisa Levin
Thursday, March 07, 2019
Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO
Shanthi Rexaline
Wednesday, March 06, 2019
Pure Bioscience Q2 EPS $(0.02) Up From $(0.03...
Benzinga Newsdesk
Sunday, March 03, 2019
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Shanthi Rexaline
Thursday, December 13, 2018
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Shanthi Rexaline
Earnings Scheduled For December 13, 2018
Lisa Levin
Saturday, December 08, 2018
The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
Shanthi Rexaline
Wednesday, August 22, 2018
Everything You Need To Know From The Cannabis Capital Conference
Hannah Genig
Thursday, December 14, 2017
PURE Bioscience Reports Q1 EPS $(0.04) vs $(0...
Benzinga
Thursday, June 08, 2017
PURE Bioscience Reports Q3 EPS $(0.03) vs $(0...
Benzinga
Tuesday, June 14, 2016
Franchise Brands Reports 39.02% Stake in Pure...
Benzinga
Thursday, June 09, 2016
PURE Bioscience Reports Q3 EPS $(0.02) Vs Pri...
Benzinga
Thursday, June 11, 2015
PURE Bioscience Reports Q3 Loss of $0.05/Shar...
Benzinga
Monday, April 07, 2014
Why Agios Pharmaceuticals (AGIO) Could Be Positioned for a Slump? - Tale of the Tape
Benzinga
Thursday, March 13, 2014
PURE Bioscience, Inc. Reports Q2 EPS of $(0.10); Revenue of $41.0K
Benzinga
Thursday, December 12, 2013
PURE Bioscience, Inc. Reports Q1 EPS of $(0.19); Revenue of $115.0K
Benzinga
Thursday, April 25, 2013
PURE Bioscience Receives Favorable NASDAQ Listing Decision
Benzinga
Tuesday, February 26, 2013
PURE Bioscience, Inc. Reports Q2 EPS of $(0.17); Revenue of $263.0K
Benzinga
Friday, February 01, 2013
Pure Bioscience Registers Up to $15M Shares
Benzinga
Friday, December 14, 2012
UPDATE: Zacks Downgrades Pure Bioscience to Neutral from Outperform on Commercialization Delays
Benzinga
Thursday, December 13, 2012
Zacks Research Downgrades PURE Bioscience, Inc. to Neutral
Benzinga
Wednesday, December 12, 2012
PURE Bioscience, Inc. Reports Q1 EPS of $(0.25), Up 47% YOY; Revenue of $110.0K, Down 57% YOY
Benzinga
Wednesday, October 03, 2012
PURE Biosences Says Continuing to Test SDC in Produce
Benzinga
Thursday, September 27, 2012
PURE Bioscience Partners with Italian Export Company TICE
Benzinga
Monday, September 24, 2012
PURE Bioscience Regains Compliance with Nasdaq Listing Requirements
Benzinga
Tuesday, September 11, 2012
Stocks Hitting 52-Week Lows
Benzinga
Tuesday, August 14, 2012
PURE Bioscience Reports 1-for-8 Reverse Stock Split
Benzinga
Monday, April 30, 2012
PURE Bioscience Partners with Intercon Chemical Company
Benzinga
Tuesday, April 24, 2012
PURE Bioscience Announces Positive Research from University of Arkansas
Benzinga
Friday, December 23, 2011
Coalition to Save Pure Files Proxy Documents With SEC, Urges Pure's Board to Set an Annual Meeting Date
Benzinga
Thursday, December 15, 2011
PURE Bioscience Announces Purchase Agreements for up to $10 Million with Lincoln Park Capital Fund, LLC
Benzinga
Thursday, July 07, 2011
PURE Bioscience Announces GRAS Determination for SDC as a Contact Biocide in Food Processing
Benzinga
Thursday, June 23, 2011
A Peek Into The Market Before The Trading Starts
Benzinga
PURE Bioscience Receives Health Canada Approval for PURE Hard Surface Disinfectant
Benzinga
Wednesday, June 15, 2011
A Peek Into The Market Before The Trading Starts
Benzinga
PURE Bioscience Obtains NSF Registration for PURE Hard Surface as No-Rinse Sanitizer in Food Processing Areas
Benzinga
Thursday, June 09, 2011
PURE Bioscience Names Craig Johnson as Chief Financial Officer
Benzinga
Monday, June 06, 2011
UPDATE: E. Coli Sympathy Stocks Include PURE Bioscience, Strategic Dianostics, Nymox Pharma, Life Technologies, and Food Technology Service
Benzinga
Thursday, March 17, 2011
PURE Bioscience Reports Q2 EPS of $(0.07)
Benzinga
Thursday, December 16, 2010
PURE Bioscience Announces Ten Year $144 Million Contract
Benzinga
Wednesday, December 15, 2010
PURE Bioscience Reports First Quarter EPS of $(0.06)
Benzinga
Friday, October 29, 2010
PURE Bioscience Falls on Q4 Loss (PURE)
Benzinga
Show More
